From Silos to Synergy: Connecting Clinical Evaluation, Risk Management, and PMS/PMCF Under the MDR
Under Regulation (EU) 2017/745, aka MDR, medical device manufacturers face stricter requirements for demonstrating safety, performance, and clinical benefit throughout a product’s lifecycle. While many organizations treat Clinical Evaluation, Risk Management, and Post-Market Surveillance/Post-Market Clinical Follow-up (PMS/PMCF) as separate regulatory obligations, the MDR clearly expects these processes to be interconnected, forming a continuous feedback loop.
Clinical evidence must be supported by real-world data; emerging risks must be evaluated against clinical benefits, and post-market findings must feed directly back into the risk management and clinical evaluation documentation. When these processes operate in isolation, critical insights can be missed, leading to compliance gaps and delayed regulatory decisions. This article explores why these three processes are fundamentally interlinked and how integrating them strengthens regulatory compliance and patient safety.
Table of Contents
The Clinical Lifecycle Loop: Connecting Clinical Evidence, Risk, and Post-Market Insights
Under the previous MDD framework, clinical evaluations were required but often treated as a once-off task for CE marking. Updates typically occurred only during recertification or after major device changes, with limited connection to risk management or post-market data. The MDR, however emphasizes a continuous clinical lifecycle approach, where pre-market evidence and post-market data are part of the same system rather than separate regulatory tasks. Moreover, the MDR has transformed clinical evaluation into a continuous lifecycle process, fully integrated with risk management and PMS/PMCF to ensure safety, performance, and patient protection throughout a device’s market presence.
Three core pillars now form a continuous loop:
- Clinical Evaluation: Demonstrates safety, performance, and clinical benefit using clinical data.
- Risk Management: Identifies, evaluates, and mitigates risks associated with device use.
- PMS and PMCF: Collect and analyze real-world data after market launch.
Instead of existing as independent processes and documents, MDR requires these processes to continuously inform each other.
This circular flow ensures that safety and performance are assessed throughout the entire product lifecycle.
For Example
PMS finding may identify new incidents („adverse events“) or device misuse patterns. These insights must update the Risk Management File.
Why it matters?
Managing Clinical Evaluation, Risk Management, and PMS/PMCF in isolation can create significant regulatory and operational risks. When these processes operate in silos, manufacturers may face:
- Incomplete risk assessments: Emerging real-world data may be overlooked.
- Outdated clinical evidence: CER updates may not reflect the latest PMS findings.
- Unnecessary findings: Notified bodies may flag inconsistencies and gaps in traceability.
- Slower MDR certification or recertifications: Disconnected processes can delay submissions and CE marking.
Notified bodies expect clear, documented links between these three processes. During audits, they frequently check whether:
- Risk control measures in the Risk Management File are supported by clinical evidence.
- PMS signals trigger timely updates to both risk management and clinical evaluation.
- PMCF activities are designed to address residual risks or gaps identified in the CER.
Without integrated workflows, demonstrating this traceability can be resource-intensive and error-prone, increasing the likelihood of compliance issues. By connecting these processes, manufacturers can maintain up-to-date clinical evidence, reduce risk, and streamline regulatory readiness.
clinical lifecycle support by pro-liance
An integrated, evidence-based service that aligns Clinical Evaluation, Risk Management and Post-Market Surveillance across the clinical lifecycle of a medical device.
Impact on manufacturers
For regulatory and clinical teams, the MDR lifecycle approach means greater cross-functional collaboration across departments such as:
- Clinical affairs
- Regulatory affairs
- Quality management
- Post-market surveillance
- Risk management
Organizations must also ensure data transparency and accessibility across these functions.
When integrated properly, this approach provides several advantages:
- Faster response to safety signals through immediate feedback loops.
- Stronger clinical evidence supporting benefit-risk conclusions.
- Smoother regulatory submissions and audits, with clear traceability between clinical data, risk, and PMS findings.
- Improved patient safety through proactive lifecycle management rather than reactive problem-solving.
Ultimately, the MDR encourages manufacturers to shift from isolated documentation to a connected, lifecycle-driven approach, creating both compliance assurance and operational efficiency. This allows manufacturers to proactively manage device safety rather than react to compliance issues.
Practical takeaway
To align with MDR expectations, manufacturers should move toward integrated lifecycle management rather than isolated documentation processes.
Key steps include:
- Establishing shared data inputs between Clinical Evaluation, Risk Management, and PMS/PMCF
- Creating cross-functional reviews
- Ensuring traceability between risk signals, clinical evidence, and post-market data
- Using centralized systems or workflows to manage lifecycle data
This integrated approach ensures that clinical evidence, safety monitoring, and risk evaluation evolve together throughout the product lifecycle.
Best Practices for Integrating Clinical Evaluation, Risk Management, and PMS/PMCF
Successfully linking these processes requires structured collaboration and aligned documentation strategies.
Key best practices include:
- Start with integration during development
Clinical strategy and risk analysis should begin early in product development. Early alignment helps ensure that clinical investigations address known risk areas and support a clear pathway to market, while also laying the groundwork for future post-market activities.
- Use shared data sources
Clinical Evaluation, Risk and PMS teams should work from the same evidence repositories, allowing real-world data to be efficiently incorporated into CER updates, risk reviews and PMS documentation.
- Align update cycles
Many organizations still update CER, Risk Management Files, and PMS reports /PSURs / PMCF Evaluation Reports separately. Aligning review timelines ensures that new findings are reflected consistently across documents.
- Maintain clear traceability
Notified bodies expect to see direct connections between:
- Identified risks
- Clinical evidence supporting benefit-risk
- PMS signals and PMCF data
Traceability matrices and cross-referencing can help demonstrate this linkage. In practical terms, this may look like a simple table or mapping system where each risk is linked to its corresponding clinical data source and post-market measure. This makes it easier to show regulators how emerging data flows back into risk assessment and clinical evaluation, ensuring consistency across all documentation.
When implemented effectively, these practices reduce compliance risk and create a more resilient regulatory and clinical lifecycle strategy.
Conclusion
Under the MDR, Clinical Evaluation, Risk Management, and PMS/PMCF are not standalone compliance activities—they are interconnected elements of a continuous clinical lifecycle. Real-world data must inform risk assessments, risk evaluations must support clinical conclusions regarding the benefit-risk profile, and clinical evidence must evolve as new safety information emerges.
Manufacturers that still manage these processes independently risk inconsistencies and data gaps when under Notified Body reviews. In addition, processes operating in silo are inefficient. By adopting an integrated lifecycle approach, organizations can strengthen compliance, improve transparency, and even be more efficient to better safeguard patient safety.
To support medical device manufacturers, PRO-LIANCE offers a bundled Clinical Lifecycle Support Service that integrates Clinical Evaluation, Risk Management, and PMS/PMCF into a single coordinated service. This approach ensures seamless data flow, improved traceability, and connected clinical evidence throughout the entire device lifecycle.
Categories: Clinical Evaluation
- back to overview
Share this post:
NEWSLETTER
Subscribe to our newsletter and get access
to our free Compliance Compass.
READ MORE
RELATED TOPICS
- Clinical Evaluation
- Biological Evaluation
- State of the Art
- Regulatory Affairs
- News